Page of

Share this page

Share this page

Share this page

Share this page

Zostavax - Merck

Prix Galien USA Award Laureates Book

Leave a 'Tweet'.

Add your tribute to this Research Team here in words, pictures and video clips.

Dear Colleague, As a way of celebrating and sharing and sharing the Galien Awards, a page has been created within the $bookTitle$. Here we can all share our memories – through stories, thoughts, messages, photographs and videos. If you would like to visit the page please go to $findPersonLink Thank you,
Previous Page Next

Winning Products 2013 by: Galien Foundation

Date added: 18 Mar 2014

2013 - Best Biotechnology Product: Zostavax® - Merck

Development of Zostavax® represented a totally new paradigm for vaccination; the goal was to prevent clinical disease caused by reactivation of latent infection, rather than to prevent primary infection. At the time of the development work, there was considerable uncertainty regarding whether such a goal was feasible in light of the immunosenescence that arises in older adults, since shingles is believed to be caused by waning immunity and the inability of the immune system to respond suitably to control varicella-zoster virus (VZV) reactivation. Development of vaccines against herpes viruses—the family of viruses to which VZV belongs—continues even today to be extremely challenging.

Research Team 2013 Index Previous